ERBB2 and breast carcinoma: The surrogate intrinsic subtypes are typically used clinically and are based on histology and immunohistochemistry expression; the subtypes of breast cancer have been identified as Luminal A-like, Luminal B-like HER2−, Luminal B-like HER2+, HER2-enriched, and Triple-negative.